As of October 22, 2026, Sanofi ADR (SNY) trades at $41.92. No model fair value is published for SNY. SNY reports its financial statements in EUR. Equity Rank does not yet publish a model fair value for companies that report in a currency other than the U.S. dollar.
Source: Equity Rank — SNY valuation (data as of 2026-10-22). The full page shows the company’s fundamental profile and earnings data.
Sanofi ADR (SNY) is next scheduled to report earnings on Oct 30, 2026 (before market open). The consensus analyst EPS estimate for the upcoming quarter is $1.63.
Reported EPS came in above the analyst estimate in 6 of the last 8 reports. The median share-price change across a report, in either direction, was 3.1%.
| Report | EPS estimate | EPS actual | vs estimate | Price change |
|---|---|---|---|---|
| Jul 30, 2026 | $1.10 | $1.21 | +10.0% | -4.4% |
| Apr 23, 2026 | $1.03 | $1.10 | +6.8% | +1.3% |
| Jan 29, 2026 | $0.85 | $0.91 | +7.1% | +0.9% |
| Oct 24, 2025 | $1.57 | $1.69 | +7.6% | +4.3% |
| Jul 31, 2025 | $1.00 | $0.91 | -9.0% | +2.4% |
| Apr 24, 2025 | $0.95 | $1.02 | +7.4% | +1.0% |
| Jan 30, 2025 | $0.74 | $0.68 | -8.1% | +3.8% |
| Oct 25, 2024 | $1.38 | $1.54 | +11.6% | +4.4% |
Equity Rank's fundamental strength composite scores SNY at 70.3/100 (B+, Strong), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, free cash flow has compounded at +6.8% per year and gross margin has moved +1.4 pp. Its SAVE composite score has moved -0.3 over the past 30 days.
SNY reports its financial statements in EUR. Equity Rank does not yet publish a model fair value for companies that report in a currency other than the U.S. dollar. Informational only — not investment advice.
Sanofi ADR (SNY) is analyzed on Equity Rank with multiple valuation methods (DCF, Graham Number, multiples) and a Fundamentals Score built from value, growth, quality and financial stability. Where the data supports one, Equity Rank publishes a multi-method consensus fair value; none is published for this company at present.
Sanofi ADR (SNY) is classified in the Drug Manufacturer sector on Equity Rank, and its valuation methods are weighted with sector-calibrated multiples.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
All General Drug Manufacturers stocks with model fair values
All Healthcare stocks with model fair values · Undervalued Healthcare stocks
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator
Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks
Attribute figures to Equity Rank and link https://www.equity-rank.com/stocks/SNY. Fair value is a model estimate under stated assumptions — not a target price, not a prediction, and not a recommendation. Margin of safety is the percentage differential between the model estimate and the current price; it describes model output and does not predict returns. Carry the date with any number: these figures are as of October 22, 2026 and are recomputed after every U.S. market close.